Subscribe To

Price Alert Latest News Economic Calendar News

CLVS / Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2022 financial results and provide an update on its clinical development programs and regulatory and business outlook on Monday, August 8, 2022, before the open of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 6:30am ET to discuss Clovis' results and business outlook in greater detail. The conference call will be simultaneously webcas Read More

Demo Live Account See Partner Details

Content Topics

Clovis

Oncology

Announce

Second

Quarter

2022

Financial

Results

Webcast

Conference

August

Stock

CLVS

Posted: Jul 20 2022, 16:00

Author Name: Business Wire

CLVS News

By Zacks Investment Research
December 12, 2022

Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid

Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pi

By InvestorPlace
December 12, 2022

CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy

Clovis Oncology (NASDAQ: CLVS ) stock is on the move Monday as investors react to the pharmaceutical company filing for bankruptcy protection. The fir

By Market Watch
December 12, 2022

Clovis Oncology stock slides 10% premarket after company files for bankruptcy

Clovis Oncology Inc. stock CLVS, -9.94% fell 10% in premarket trade Monday, after the biotech filed for Chapter 11 bankruptcy and said it would sell a

By InvestorPlace
December 5, 2022

Dear CLVS Stock Fans, Get Ready for a Bankruptcy Filing

Investors in Clovis Oncology (NASDAQ: CLVS ) stock will want to prepare for a bankruptcy filing following a warning from the pharmaceutical company. A

By Zacks Investment Research
November 25, 2022

Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why

Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.

By Zacks Investment Research
November 21, 2022

Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)

Clovis (CLVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong a

By InvestorPlace
November 14, 2022

Clovis Oncology (CLVS) Stock Pops After Bankruptcy Warning

There's nothing like a good old-fashioned bankruptcy warning to make a stock pop on a given day. Today, the latest speculative frenzy appears to be un

By Zacks Investment Research
September 7, 2022

Clovis (CLVS) Down 12.6% Since Last Earnings Report: Can It Rebound?

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.